OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catherine Shaffer is a contributing writer to BioPharm International, email@example.com.
Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.